Moreover, when incorporating our previous findings34, we found that these approved drug targets were also highly prioritised in their respective immune diseases, including CD80/86, IFNAR1/2, IL1B, IL6R, JAK1/2, TLR7, and TNF (Fig. 3d, e and Supplementary Data 4). Here, JAK1 is linked to immune system disorder.